Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Hospitals-II00:59

Hospitals-II

1.2K
Hospitals provide inpatient and outpatient services. Inpatient services provide care to patients that stay in the hospital for an extended period, ranging from days to months. Examples of inpatient services include intensive care units, hospital wards, or surgeries. Outpatient services provide care to patients who come to a hospital for a diagnostic or treatment but do not stay overnight —for example, diagnostic tests, surgical procedures, or health education.
Nurses that work in...
1.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

822
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
822
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

3.2K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.2K
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

757
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
757
Hospitals-I01:28

Hospitals-I

1.6K
Hospitals offer medical and surgical care to the sick and injured, along with accommodation while they recover. At the same time, they also provide outpatient, emergency, psychiatric, and rehabilitation services to meet various community needs. In addition to providing medical care, hospitals also act as hubs for medical research and training. Hospitals use clinical procedures and evidence-based practice standards to deliver patient care. To deliver safe and efficient care, a nurse must stay up...
1.6K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

292
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
292

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Galectin-3 and incidence of atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study.

American heart journal·2017
Same author

Accuracy of Self-Reported Heart Failure. The Atherosclerosis Risk in Communities (ARIC) Study.

Journal of cardiac failure·2017
Same author

Gamma prime (γ') fibrinogen and carotid intima-media thickness: the Atherosclerosis Risk in Communities study.

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2017
Same author

Cardiovascular Event Prediction by Machine Learning: The Multi-Ethnic Study of Atherosclerosis.

Circulation research·2017
Same author

Failure to replicate thrombomodulin genetic variant predictors of venous thromboembolism in African Americans.

Blood·2017
Same author

Association of Educational Attainment With Lifetime Risk of Cardiovascular Disease: The Atherosclerosis Risk in Communities Study.

JAMA internal medicine·2017

Video Experimental Relacionado

Updated: Jan 25, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K

Troponina I de alta sensibilidad y eventos coronarios incidentes, accidente cerebrovascular, hospitalización por

Xiaoming Jia1, Wensheng Sun1, Ron C Hoogeveen1

  • 1Baylor College of Medicine, Houston, TX (X.J., W.S., R.C.H., V.N., C.M.B.).

Circulation
|April 30, 2019
PubMed
Resumen

La elevación de la troponina I de alta sensibilidad (hs-TnI) está relacionada con un mayor riesgo de enfermedad cardiovascular (ECV) y mortalidad en la población general. El hs-TnI y la hs-troponina T ofrecen información complementaria para predecir los eventos de ECV.

Palabras clave:
Los biomarcadoresEnfermedades cardiovascularesLa troponina también

Más Videos Relacionados

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

557

Videos de Experimentos Relacionados

Last Updated: Jan 25, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.0K
Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.9K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

557

Área de la Ciencia:

  • Cardiología
  • Los biomarcadores
  • Salud pública

Sus antecedentes:

  • Se evaluó la asociación de la troponina I de alta sensibilidad (hs-TnI) con la enfermedad cardiovascular incidente (ECV) y la mortalidad.
  • Se utilizó una muestra comunitaria (n=8121) del estudio ARIC sin ECV previa.

Objetivo del estudio:

  • Determinar la asociación entre los niveles de hs-TnI y varios resultados incidentes de ECV y la mortalidad por cualquier causa.
  • Para comparar el poder predictivo de la hs-TnI con la troponina de alta sensibilidad T (hs-TnT).
  • Evaluar la mejora en la predicción del riesgo de ECV añadiendo hs-TnI a los modelos de riesgo existentes.

Principales métodos:

  • Utilizó modelos de riesgos proporcionales de Cox para el análisis.
  • Se incluyeron participantes de 54 a 74 años sin ECV al inicio del estudio.
  • Modelos de predicción de riesgos construidos que incorporan hs-TnI y factores de riesgo tradicionales (ecuación de cohorte agrupada).

Principales resultados:

  • El aumento del hs-TnI (quintilo más alto) se asoció con un mayor riesgo de enfermedad coronaria (CHD), accidente cerebrovascular isquémico, ECV aterosclerótica, insuficiencia cardíaca, ECV global y mortalidad por todas las causas.
  • hs-TnI mostró asociaciones más fuertes en individuos blancos y mujeres para resultados específicos.
  • hs-TnI y hs-TnT fueron modestamente correlacionados pero complementarios en la predicción de eventos de ECV.

Conclusiones:

  • El aumento de hs-TnI es un fuerte predictor independiente de la incidencia global de ECV en la población general.
  • hs-TnI y hs-TnT proporcionan información complementaria y no redundante para la evaluación del riesgo de ECV.
  • La adición de hs-TnI mejora la predicción del riesgo de ECV aterosclerótica, insuficiencia cardíaca y ECV global.